Literature DB >> 14981738

Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.

T J Lehky1, G D Leonard, R H Wilson, J L Grem, M K Floeter.   

Abstract

Oxaliplatin, a platinum-based chemotherapeutic agent, is effective in the treatment of solid tumors, particularly colorectal cancer. During and immediately following oxaliplatin infusion, patients may experience cold-induced paresthesias, throat and jaw tightness, and occasionally focal weakness. We assessed nerve conduction studies and findings on needle electromyography of patients with metastatic colorectal cancer before and during treatment with oxaliplatin. Twenty-two patients had follow-up studies within 48 h following oxaliplatin infusions, and 14 patients had follow-up studies after 3-9 treatment cycles. Repetitive compound muscle action potentials and neuromyotonic discharges were observed in the first 24-48 h following oxaliplatin infusion, but resolved by 3 weeks. After 8-9 treatment cycles, sensory nerve action potential amplitudes declined, without conduction velocity changes or neuromyotonic discharges. The acute neurological symptoms reflect a state of peripheral nerve hyperexcitability that likely represents a transient oxaliplatin-induced channelopathy. Chronic treatment causes an axonal neuropathy similar to other platinum-based chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981738     DOI: 10.1002/mus.10559

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  90 in total

Review 1.  Neurologic toxicities of cancer therapies.

Authors:  Robert Cavaliere; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Acute, generalised but transient muscle cramping and weakness shortly after first oxaliplatin infusion.

Authors:  Elisabeth Krexner; Anika Stickler; Christian Prainer; Josef Finsterer
Journal:  Med Oncol       Date:  2012-06-06       Impact factor: 3.064

3.  Evaluation of efficacy and safety of generic levofolinate in patients who received colorectal cancer chemotherapy.

Authors:  Hironori Fujii; Hirotoshi Iihara; Koji Yasuda; Katsuhiko Matsuura; Takao Takahashi; Kazuhiro Yoshida; Yoshinori Itoh
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

4.  Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

Authors:  Axel Grothey; Daniel A Nikcevich; Jeff A Sloan; John W Kugler; Peter T Silberstein; Todor Dentchev; Donald B Wender; Paul J Novotny; Umesh Chitaley; Steven R Alberts; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

5.  N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data.

Authors:  Peng-Chan Lin; Ming-Yang Lee; Wei-Shu Wang; Chueh-Chuan Yen; Ta-Chung Chao; Liang-Tsai Hsiao; Muh-Hwa Yang; Po-Min Chen; Kon-Ping Lin; Tzeon-Jye Chiou
Journal:  Support Care Cancer       Date:  2006-02-01       Impact factor: 3.603

Review 6.  Converting cold into pain.

Authors:  Carlos Belmonte; James A Brock; Felix Viana
Journal:  Exp Brain Res       Date:  2009-04-28       Impact factor: 1.972

7.  Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat.

Authors:  Elizabeth K Joseph; Jon D Levine
Journal:  J Pain       Date:  2009-02-23       Impact factor: 5.820

Review 8.  [Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].

Authors:  T Kowalski; C Maier; A Reinacher-Schick; U Schlegel
Journal:  Schmerz       Date:  2008-02       Impact factor: 1.107

9.  Clinical and experimental study of oxaliplatin in treating human gastric carcinoma.

Authors:  Wan-Long Lin; Ding-Guo Li; Qiang Chen; Han-Ming Lu
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

10.  Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

Authors:  Deirdre R Pachman; Rui Qin; Drew K Seisler; Ellen M L Smith; Andreas S Beutler; Lauren E Ta; Jacqueline M Lafky; Nina D Wagner-Johnston; Kathryn J Ruddy; Shaker Dakhil; Nathan P Staff; Axel Grothey; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.